Holen Sie sich die Stockscreener-App
37.16
8.18%
2.81
Handel nachbörslich:
37.18
0.02
+0.05%
Schlusskurs vom Vortag:
$34.35
Offen:
$34.45
24-Stunden-Volumen:
1.66M
Relative Volume:
1.18
Marktkapitalisierung:
$1.34B
Einnahmen:
$117.67M
Nettoeinkommen (Verlust:
$-1.88B
KGV:
-0.6138
EPS:
-60.5369
Netto-Cashflow:
$-621.36M
1W Leistung:
-3.56%
1M Leistung:
-18.56%
6M Leistung:
+64.13%
1J Leistung:
+130.38%
1-Tages-Spanne:
$33.73
$38.70
1-Wochen-Bereich:
$33.73
$38.70
52-Wochen-Spanne:
$12.33
$63.99
Grail Inc Stock (GRAL) Company Profile
Firmenname
Grail Inc
Sektor
Branche
Telefon
(833) 694-2553
Adresse
1525 O'BRIEN DRIVE, MENLO PARK
Vergleichen Sie GRAL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
37.16 | 1.39B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-10-17 | Eingeleitet | Guggenheim | Neutral |
Grail Inc Aktie (GRAL) Neueste Nachrichten
What analysts say about GRAIL LLC stockRapid growth opportunities - Autocar Professional
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
(GRAL) Technical Data - news.stocktradersdaily.com
What drives GRAIL LLC stock priceTriple-digit profit margins - Autocar Professional
Is GRAIL LLC a good long term investmentGame-changing returns - jammulinksnews.com
GRAIL LLC Stock Analysis and ForecastPhenomenal capital appreciation - jammulinksnews.com
Grail posts latest trial data for Galleri cancer detection test - MSN
Grail’s CFO Freidin sells $311k in common stock - Investing.com India
Grail’s CFO Freidin sells $311k in common stock By Investing.com - Investing.com Nigeria
Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight’ Stance - MSN
GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission - Insider Monkey
Illumina: A Compelling Buy Despite GRAIL Divestiture and Macroeconomic Challenges - AInvest
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds - Seeking Alpha
Grail (GRAL): A High-Reward, High-Risk Play on Cancer Detection's Future - AInvest
15 Successful Spin-Off Companies and Their 2025 Returns - Insider Monkey
GRAIL Insiders Selling US$10m In Stock Relieved As Market Cap Slides To US$1.7b - simplywall.st
GRAIL's Insider Sales: Red Flag or Strategic Move? Assessing Executive Confidence Amid Strong Financials - AInvest
(GRAL) Trading Report - news.stocktradersdaily.com
GRAIL, Inc.(NasdaqGS: GRAL) added to Russell 2500 Value Index - MarketScreener
GRAIL, Inc.(NasdaqGS: GRAL) dropped from Russell Midcap Index - MarketScreener
Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone - CancerNetwork
Morgan Stanley raises Grail stock price target to $38 on cancer test potential - Investing.com
Grail plans FDA filing for cancer blood test after new trial - pharmaphorum
Grail reports positive outcomes from registrational study of Galleri test - Yahoo Home
PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test - OncLive
Grail plans to submit updated Galleri blood test for FDA approval next year - Fierce Biotech
Grail stock gains on new data for Galleri cancer test (GRAL) - Seeking Alpha
GRAIL reports positive results from cancer detection test study By Investing.com - Investing.com Nigeria
GRAIL reports positive results from cancer detection test study - Investing.com Australia
GRAIL Announces Positive Top-Line Results From The Galleri PATHFINDER 2 Registrational Study - MarketScreener
Grail reports results from PATHFINDER 2 study - TipRanks
Revolutionary Cancer Screening Test Achieves Major Clinical Success: GRAIL's Galleri Outperforms Previous Study - Stock Titan
GRAL Stock Surges: What Drives the Excitement? - timothysykes.com
GRAIL: Too Much A Leap Of Faith (NASDAQ:GRAL) - Seeking Alpha
California State Teachers Retirement System Takes $464,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
67,288 Shares in Grail, Inc. (NASDAQ:GRAL) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
NINGI short Grail, says ‘approval and commercialization all but impossible’ - TipRanks
GRAIL stock tumbles on short-seller report By Investing.com - Investing.com Nigeria
GRAIL stock tumbles on short-seller report - Investing.com
Ningi Research Says Short Grail - marketscreener.com
3 Medical Technology Stocks Outperforming in 2025 - inkl
GRALGRAIL Reports First Quarter 2025 Financial Results - mx.advfn.com
Wellington Management Group LLP Takes Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
Two Sigma Advisers LP Makes New $345,000 Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
For FMCG Inc., the holy grail of volume growth is in sight | Company Business News - Mint
Nuveen Asset Management LLC Takes $837,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
Transcript : GRAIL, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 11 - marketscreener.com
BNP Paribas Financial Markets Invests $50,000 in Grail, Inc. (NASDAQ:GRAL) - Defense World
Ameriprise Financial Inc. Takes $681,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
GRAIL, Inc. (GRAL) Stock Analysis: Evaluating the 19.10% Revenue Growth Against Market Challenges - DirectorsTalk Interviews
96,630 Shares in Grail, Inc. (NASDAQ:GRAL) Purchased by Two Sigma Investments LP - Defense World
Finanzdaten der Grail Inc-Aktie (GRAL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):